Exacerbation of dietary steatohepatitis and fibrosis in obese, diabetic KK-Ay mice

Hepatology Research

Volumn 36, Issue 3, 2006, Pages 217-228

  Okumura, Kyoko ^a   Ikejima, Kenichi ^a   Kon, Kazuyoshi ^a   Abe, Wataru ^a   Yamashina, Shunhei ^a   Enomoto, Nobuyuki ^a   Takei, Yoshiyuki ^a   Sato, Nobuhiro ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Hepatic fibrogenesis; Leptin; Methionine and choline deficiency (MCD); Non alcoholic steatohepatitis (NASH); Oxidative stress

Indexed keywords

ADIPONECTIN; CHOLINE; MESSENGER RNA; METHIONINE; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; HIGH RISK POPULATION; INFLAMMATORY INFILTRATE; LIPID PEROXIDATION; LIVER FIBROSIS; MALE; MOUSE; MOUSE STRAIN; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN DETERMINATION; STRAIN DIFFERENCE;

EID: 33750070921     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2006.07.009     Document Type: Article

References (44)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 16 (2002) 1221-1231
2. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 6 (2002) 1649-1657
3. Diehl A.M. Nonalcoholic steatohepatitis. Semin Liver Dis 19 2 (1999) 221-229
4. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 4 (2003) 917-923
5. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 2 (2002) 367-372
6. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 114 4 (1998) 842-845
7. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37 5 (2003) 1202-1219
8. Czaja M.J. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 40 1 (2004) 19-22
9. Honda H., Ikejima K., Hirose M., et al. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36 1 (2002) 12-21
10. Ikejima K., Takei Y., Honda H., et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122 5 (2002) 1399-1410
11. Ikejima K., Honda H., Yoshikawa M., et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34 2 (2001) 288-297
12. Lang T., Ikejima K., Yoshikawa M., et al. Leptin facilitates proliferation of hepatic stellate cells through up-regulation of platelet-derived growth factor receptor. Biochem Biophys Res Commun 323 3 (2004) 1091-1095
13. Leclercq I.A., Farrell G.C., Schriemer R., and Robertson G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37 2 (2002) 206-213
14. Saxena N.K., Ikeda K., Rockey D.C., Friedman S.L., and Anania F.A. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35 4 (2002) 762-771
15. Potter J.J., and Mezey E. Leptin deficiency reduces but does not eliminate the development of hepatic fibrosis in mice infected with Schistosoma mansoni. Liver 22 2 (2002) 173-177
16. Saxena N.K., Saliba G., Floyd J.J., and Anania F.A. Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 89 2 (2003) 311-320
17. Ikeda H. KK mouse. Diabetes Res Clin Pract 24 (1994) S313-S316 Suppl
18. Miller M.W., Duhl D.M., Vrieling H., et al. Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev 7 3 (1993) 454-467
19. Siracusa L.D., Russell L.B., Eicher E.M., Corrow D.J., Copeland N.G., and Jenkins N.A. Genetic organization of the agouti region of the mouse. Genetics 117 1 (1987) 93-100
20. Iwatsuka H., Shino A., and Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol Jpn 17 1 (1970) 23-35
21. Halaas J.L., Boozer C., Blair-West J., Fidahusein N., Denton D.A., and Friedman J.M. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 94 16 (1997) 8878-8883
22. Lu D., Willard D., Patel I.R., et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 371 6500 (1994) 799-802
23. Ghoshal A.K., and Farber E. Choline deficiency, lipotrope deficiency and the development of liver disease including liver cancer: a new perspective. Lab Invest 68 3 (1993) 255-260
24. Rinella M.E., and Green R.M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40 1 (2004) 47-51
25. Leclercq I.A., Farrell G.C., Field J., Bell D.R., Gonzalez F.J., and Robertson G.R. CYP2E1 CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105 8 (2000) 1067-1075
26. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 4 (2000) 2247-2250
27. Gressner A.M., Weiskirchen R., Breitkopf K., and Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 7 (2002) d793-d807
28. Potter J.J., Womack L., Mezey E., and Anania F.A. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 244 1 (1998) 178-182
29. y obese mice. Hepatology 40 1 (2004) 177-184
30. Kamada Y., Tamura S., Kiso S., et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125 6 (2003) 1796-1807
31. Lieber C.S. CYP2E1: from ASH to NASH. Hepatol Res 28 1 (2004) 1-11
32. Sanchez-Alcazar J.A., Schneider E., Martinez M.A., et al. Tumor necrosis factor-alpha increases the steady-state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. J Biol Chem 275 18 (2000) 13353-13361
33. Naveau S., Giraud V., Borotto E., Aubert A., Capron F., and Chaput J.C. Excess weight risk factor for alcoholic liver disease. Hepatology 25 1 (1997) 108-111
34. Raynard B., Balian A., Fallik D., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35 3 (2002) 635-638
35. Bressler B.L., Guindi M., Tomlinson G., and Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 3 (2003) 639-644
36. Hourigan L.F., Macdonald G.A., Purdie D., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29 4 (1999) 1215-1219
37. Ortiz V., Berenguer M., Rayon J.M., Carrasco D., and Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97 9 (2002) 2408-2414
38. Vaisse C., Halaas J.L., Horvath C.M., Darnell Jr. J.E., Stoffel M., and Friedman J.M. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 14 1 (1996) 95-97
39. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 6505 (1994) 425-432
40. Faggioni R., Fantuzzi G., Gabay C., et al. Leptin deficiency enhances sensitivity to endotoxin-induced lethality. Am J Physiol 276 1 Pt 2 (1999) R136-R142
41. Yang S., Lin H., and Diehl A.M. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 281 2 (2001) G382-G392
42. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 6704 (1998) 763-770
43. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 11 (2002) 1288-1295
44. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 8 (2001) 941-946